Compass Pathways President Steps Down To An Advisory Role

Compass Pathways (Nasdaq: CMPS) announced this morning major changes to its executive team. One of its co-founders, President and Chief Business Officer Lars Wilde is stepping down to take a senior advisory role.

“We have built an amazing company at COMPASS and I am grateful to everyone who continues to support us,” Wilde said in a statement. “This is a natural time for me to transition to an advisory role and I am proud to be able to continue working with COMPASS.”

The move is effective as of January 1, 2022.

Wilde is said to have been integral to the company’s strategic and operational efforts, “including fundraising, business development, and the development of its Discovery Center.”

The firm also announced Matthew Owens as its General Counsel and Chief Legal Officer starting February 1, 2022, while Mike Falvey was announced as the incoming CFO earlier this month.

Compass Pathways last traded at US$23.73 on the Nasdaq.


Information for this briefing was found via Edgar and Compass Pathways. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why the Market May Be Misreading Iran | David Woo

Why US Fertilizer Supply Could Matter a Lot More Now | Pat Varas – Sage Potash

Roscan Gold: Mali Discount Hits Kandiole PEA

Recommended

Antimony Resources Expands New Discovery Following Trenching

Silver47 Kicks Off 7,000-Meter Drill Campaign at Nevada’s Hughes Project

Related News

Compass Pathways Granted Its Tenth Overall Patent Related To Psilocybin

Compass Pathways (NASDAQ: CMPS) this morning issued a brief release, indicating it has been granted...

Tuesday, November 23, 2021, 07:55:20 AM

Andrew Left’s Citron Research Places $100 Price Target On Compass Pathways

Andrew Left of Citron Research today released a research paper on Compass Pathways (NASDAQ: CMPS),...

Monday, October 5, 2020, 07:01:00 PM

Compass Pathways Sees “Reduction In Depressive Symptom” In Phase IIb Psilocybin Clinical Trial

Compass Pathways (Nasdaq: CMPS) announced today that its phase IIb clinical trial of COMP360 psilocybin therapy...

Tuesday, November 9, 2021, 12:33:00 PM

Compass Pathways, Psilocybin Research Firm, Files For Nasdaq IPO

It appears that some authenticity and validation might be coming to the psychedelics space. Compass...

Saturday, August 29, 2020, 11:43:00 AM

Compass Pathways To Start Phase II Trial For Psilocybin PTSD Therapy

Compass Pathways (Nasdaq: CMPS) this morning announced that it will be launching the phase II...

Wednesday, November 3, 2021, 09:52:00 AM